NCT01181726已完成1 期
A Two-Way Crossover, Open-Label, Single-Dose, Fed, Bioequivalence Study of Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg Versus Activella® (1 mg Estradiol/0.5 mg Norethindrone Acetate) Tablets in Normal, Healthy, Post-Menopausal Female Subjects.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- AUC0-t of Norethindrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
研究概览
简要总结
The objective of this study was to determine and compare the rate and extent of absorption of norethindrone and unconjugated estradiol from a test formulation of Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg versus the reference Activella® (1 mg estradiol/0.5 mg norethindrone acetate) Tablets under fed conditions.
详细描述
Criteria for Evaluation: FDA Bioequivalence Criteria
Statistical Methods: FDA Bioequivalence Statistical Methods
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Non-smoking or smoking (up to 10 cigarettes/day), physiologically or surgically post-menopausal female within the age range of 18-65 years.
- •17β-estradiol serum levels of ≤ 92 pmol/L and follicle-stimulating hormone (FSH) of ≥ 40 IU/L.
- •Body Mass Index (BMI) greater than or equal to 19.0 kg/m2 and less than or equal to 30.0 kg/m
- •Normal findings in the physical examination, 12-lead electrocardiogram (ECG) and vital signs.
- •Hemoglobin ≥ 115 g/L.
- •Normal pap smear.
- •Normal mammogram within 1 year for subjects who are over the age of 50 years.
- •Negative for drugs of abuse and alcohol.
- •Negative for hepatitis B-surface antigen, hepatitis C, and Human Immunodeficiency Virus (HIV).
- •No clinical laboratory values outside the acceptable range unless the Principal Investigator or Sub-Investigator decides that they are not clinically significant (NCS).
- •Negative for pregnancy.
- •Subjects who are surgically post-menopausal with an intact uterus (i.e. bilateral oophorectomy) for at least 6 months, or physiologically post-menopausal (i.e. spontaneous amenorrhea) for at least 1 year, and who will adhere to contraceptive requirements from at least 10 days before Period I check-in, during the study and up until 1 month after the end of the study.
- •Availability of the subject for the entire study period and willingness of the subject to adhere to protocol requirements, as evidenced by a signed ICF.
排除标准
- •Known history of hypersensitivity to norethindrone and estradiol combinations and/or norethindrone, and/or estradiol.
- •Known history or presence of cardiac, pulmonary, gastrointestinal, endocrine, musculoskeletal, neurological, or hematological diseases, malignancies, or migraines, unless deemed not clinically significant by the Principal Investigator or Sub-Investigator.
- •Known history of liver, kidney, and/or gallbladder dysfunction/disease, chronic diarrhea, or inflammatory bowel diseases.
- •Known history or presence of cerebrovascular diseases or venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis.
- •Any history of stroke.
- •Presence of any significant physical or organ abnormality.
- •History of osteoporosis.
- •History or presence of fibrocystic breast disease.
- •History or presence of breast, endometrial, cervical, and/or uterine carcinoma.
- •Any illness during the 4 weeks before this study, unless deemed not clinically significant by the Principal Investigator or Sub-Investigator.
- •Any history or evidence of psychiatric or psychological disease, unless deemed not clinically significant by the Principal Investigator or the Sub-Investigator.
- •Any history or abnormal vaginal bleeding, unless deemed not clinically significant by the Principal Investigator or the Sub-Investigator.
- •Any history of asthma (after 12 years of age).
- •Evidence of pregnancy or lactation.
- •Any history of severe allergic reaction (including drugs, food, insect bites, environmental allergens).
- •Known history or presence of food allergies, or any condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
- •Any history or drug abuse.
- •Any recent history of alcohol abuse (less than 1 year).
- •Use of any prescription medication within 30 days preceding this study.
- •Use of hormone replacement therapy within 30 days before drug administration.
- •Use of over-the-counter (OTC) medication or any herbal supplement within the 7 days preceding this study.
- •Use of hormonal contraceptives, oral, transdermal, implant within 30 days before drug administration or a depot injection or progestogen drug within 1 year before the drug administration.
- •Depot injection of any drug within 6 months.
- •Blood draws within 56 days preceding this study, during the conduct of any clinical study at another facility, or within the lockout period specified by previous study.
- •Blood donations within 56 days preceding this study.
- •Participation as a plasma donor in a plasmapheresis program within 7 days preceding this study.
- •Participation in a clinical trial with an investigational drug within 30 days preceding this study.
- •Intolerance to venipuncture.
研究组 & 干预措施
Investigational Test Product
Experimental
Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg
干预措施: Estradiol/Norethindrone acetate (Drug)
Reference Listed Drug
Active Comparator
Activella® (1 mg estradiol/0.5 mg norethindrone acetate) Tablets
干预措施: Activella® (Drug)
结局指标
主要结局
AUC0-t of Norethindrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
时间窗: Blood samples collected over a 36 hour period.
Bioequivalence based on Norethindrone AUC0-t.
Cmax of Norethindrone (Maximum Observed Concentration of Drug Substance in Plasma)
时间窗: Blood samples collected over a 36 hour period.
Bioequivalence based on Norethindrone Cmax.
AUC0-inf of Norethindrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
时间窗: Blood samples collected over a 36 hour period.
Bioequivalence based on Norethindrone AUC0-inf.
Cmax of Corrected Total Estrone(Maximum Observed Concentration of Drug Substance in Plasma)
时间窗: Blood samples collected over a 72 hour period.
Bioequivalence based on Corrected Total Estrone Cmax.
AUC0-t of Corrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
时间窗: Blood samples collected over a 72 hour period.
Bioequivalence based on Corrected Total Estrone AUC0-t.
AUC0-inf of Corrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
时间窗: Blood samples collected over a 72 hour period.
Bioequivalence based on Corrected Total Estrone AUC0-inf.
次要结局
- Cmax of Uncorrected Total Estrone(Maximum Observed Concentration of Drug Substance in Plasma)(Blood samples collected over a 72 hour period.)
- AUC0-t of Uncorrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)(Blood samples collected over a 72 hour period.)
- AUC0-inf of Uncorrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)(Blood samples collected over a 72 hour period.)
- Cmax of Uncorrected Unconjugated Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)(Blood samples collected over a 72 hour period.)
- AUC0-t of Uncorrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)(Blood samples collected over a 72 hour period.)
- AUC0-t of Uncorrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)(Blood samples collected over a 72 hour period.)
- AUC0-t of Corrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)(Blood samples collected over a 72 hour period.)
- AUC0-inf of Corrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)(Blood samples collected over a 72 hour period.)
- Cmax of Corrected Unconjugated Estrone(Maximum Observed Concentration of Drug Substance in Plasma)(Blood samples collected over a 72 hour period.)
- AUC0-t of Corrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)(Blood samples collected over a 72 hour period.)
- AUC0-inf of Corrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)(Blood samples collected over a 72 hour period.)
- AUC0-inf of Uncorrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)(Blood samples collected over a 72 hour period.)
- Cmax of Uncorrected Unconjugated Estrone(Maximum Observed Concentration of Drug Substance in Plasma)(Blood samples collected over a 72 hour period.)
- AUC0-inf of Uncorrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)(Blood samples collected over a 72 hour period.)
- Cmax of Corrected Unconjugated Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)(Blood samples collected over a 72 hour period.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fasting ConditionsHealthyNCT01157182Teva Pharmaceuticals USA36
已完成
1 期
Levetiracetam 1000 mg Under Non-Fasting ConditionsHealthyNCT00859430Teva Pharmaceuticals USA22
已完成
1 期
Levetiracetam 1000 mg Under Fasting ConditionsHealthyNCT00859521Teva Pharmaceuticals USA30
已完成
1 期
Buprenorphine 8 mg Sublingual Tablets Under Fasting ConditionsHealthyNCT01157169Teva Pharmaceuticals USA40
已完成
1 期
Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed ConditionHealthyNCT00939835Torrent Pharmaceuticals Limited